HLB Pep Co. Ltd.
KKRX:1963004,220.00
KRW
-60.00
(-1.40%)
ISIN
KR7196300008
Return %
Stock
S&P 500
1Y
-37.01
14.20
3Y
-72.79
81.12
5Y
-77.13
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Kyung-jae Shim
- Full Time Employees
- 88
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Gwangju South Korea
- IPO Date
- Dec 7, 2016
- Website
- hlbpep.co.kr
- Similar Companies
- Business
- HLB Pep Co., Ltd. is a South Korea-based biotechnology company and contract development and manufacturing organization (CDMO) that specializes in the research, development, synthesis, and commercial production of peptide active pharmaceutical ingredients, biomaterials, and therapeutic drug candidates. Founded in 2000 and headquartered in Gwangju, South Korea, the company operates specialized Good Manufacturing Practice (GMP) production facilities and research centers located in Gwangju, Jangseong, and Osong, supplying commercial pharmaceutical companies, research institutions, and cosmetic manufacturers across South Korea, North America, Europe, and the wider Asia-Pacific region. The company operates across multiple specialized segments encompassing pharmaceutical APIs, custom synthesis services, cosmeceutical ingredients, research reagents, and novel drug development. Its principal products and services include: GMP-grade peptide active pharmaceutical ingredients (APIs), featuring commercial-scale production of Leuprorelin (Leuprolide acetate), Ganirelix, Vasopressin, and Desmopressin; comprehensive custom peptide synthesis services, offering customized chain lengths, high-purity formulations exceeding 98% purity, and complex chemical modifications such as phosphorylation, acetylation, methylation, cyclization, and fluorescent labeling; cosmetic peptide materials and functional biomaterials, including Acetyl Hexapeptide and Palmitoyl Hexapeptide for anti-aging, wrinkle reduction, and dermatology applications; catalog research peptides and combinatorial peptide libraries utilized in preclinical academic, diagnostic, and industrial life science research; and end-to-end CDMO/CMO services comprising process development, method validation, quality control, and regulatory documentation. In addition, the company advances an internal proprietary biopharmaceutical pipeline that includes AGM-130 for triple-negative breast cancer, AGM-212 and AGM-217 for diabetes and metabolic diseases, AGM-260 for ulcerative colitis, AGM-290 for multidrug-resistant bacterial infections, and AGM-380 for antiviral indications. In recent corporate developments, the company underwent a major ownership change and structural reorganization following its acquisition by the HLB Group in early 2025 in a transaction valued at approximately KRW 60 billion. Formerly known as AnyGen Co., Ltd., the company officially rebranded to HLB Pep Co., Ltd. in April 2025 to integrate directly into the broader HLB Group healthcare and biopharmaceutical ecosystem. Following the acquisition, the company has executed a strategic expansion into high-growth peptide segments, specifically scaling up manufacturing capabilities for glucagon-like peptide-1 (GLP-1) obesity and diabetes treatments, advancing peptide-drug conjugate (PDC) oncology research, and accelerating international Drug Master File (DMF) registrations with regulatory authorities, including the United States Food and Drug Administration (FDA), to expand its global CDMO footprint.